Incannex Healthcare Inc
IXHL0.152USD
-0.458-75.10%
Cierre 04/29, 16:00（ET）Cotizaciones retrasadas 15 min
2.70MCap. mercado
PérdidaP/E TTM
Más Datos de Incannex Healthcare Inc Compañía
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Información de la empresa
Código de la empresaIXHL
Nombre de la empresaIncannex Healthcare Inc
Fecha de salida a bolsaMar 18, 2022
Fundada en2023
Director ejecutivoMr. Joel Latham
Número de empleados9
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 18
Dirección18 East 50th Street
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal10022
Teléfono
Sitio Web
Código de la empresaIXHL
Fecha de salida a bolsaMar 18, 2022
Fundada en2023
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
--
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
--
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
169.20K
+146.20%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
--
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
--
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
169.20K
+146.20%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
--
--
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2022
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Australia
74.00K
0.00%
Por negocio
Por región
Sin datos
Accionista
Hora de actualización: mar., 8 de abr
Hora de actualización: mar., 8 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
5.73%
Valentine (Troy Robert)
3.76%
Anastassov (George)
2.79%
Other
73.71%
Estadísticas de accionistas
Accionista
Proporción
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
5.73%
Valentine (Troy Robert)
3.76%
Anastassov (George)
2.79%
Other
73.71%
Tipo
Accionista
Proporción
Individual Investor
16.57%
Corporation
14.01%
Investment Advisor
0.82%
Research Firm
0.37%
Investment Advisor/Hedge Fund
0.07%
Other
68.18%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
36
9.08M
33.58%
+3.85M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
2023Q1
10
20.53K
0.03%
-60.83K
2022Q4
10
50.18K
0.08%
-3.79K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
L1 Capital Global Opportunities Master Fund Ltd.
1.93M
7%
+1.93M
--
Mar 10, 2025
S.H.N. Financial Investments Ltd
1.93M
7%
+1.93M
--
Mar 10, 2025
Latham (Joel)
1.58M
5.73%
--
--
Oct 21, 2024
Valentine (Troy Robert)
1.04M
3.76%
--
--
Oct 21, 2024
Anastassov (George)
769.72K
2.79%
--
--
Oct 21, 2024
Changoer Lekhram
639.55K
2.32%
--
--
Oct 21, 2024
Widdows (Peter)
270.85K
0.98%
--
--
Oct 21, 2024
Swan (Joseph)
169.20K
0.61%
+100.48K
+146.20%
Oct 23, 2024
AdvisorShares Investments, LLC
165.50K
0.6%
+38.51K
+30.32%
Dec 31, 2024
Clark (Robert)
100.00K
0.36%
--
--
Oct 21, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
AdvisorShares Psychedelics ETF
4.37%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Proporción4.37%
Amplify Alternative Harvest ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos